TY  - JOUR 
AU  - Pérez-Gómez, Noelia
AU  - Sanz-Solas, Antonio
AU  - Cuevas, Beatriz
AU  - Cuevas, María Victoria
AU  - Alonso-Madrigal, Cristina
AU  - Loscertales, Javier
AU  - Álvarez-Nuño, Rodolfo
AU  - García, Covadonga
AU  - Zubiaur, Pablo
AU  - Villapalos-García, Gonzalo
AU  - Parra-Garcés, Raúl Miguel
AU  - Mejía-Abril, Gina
AU  - Alcaraz, Raquel
AU  - Vinuesa, Raquel
AU  - Díaz-Gálvez, Francisco Javier
AU  - González-Oter, María
AU  - García-Sancha, Natalia
AU  - Azibeiro-Melchor, Raúl
AU  - González-López, Tomás José
AU  - Abad-Santos, Francisco
AU  - Labrador, Jorge
AU  - Saiz-Rodríguez, Miriam
PY  - 2025
SN  - 1424-8247
UR  - https://hdl.handle.net/10259/11908
AB  - Background/Objectives: Ibrutinib is a selective Bruton’s tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL). This drug exhibits significant variability in response and toxicity profile, possibly due to genetic...
LA  - eng
PB  - MDPI
KW  - Chronic lymphocytic leukemia
KW  - Ibrutinib
KW  - Pharmacogenetics
KW  - Polymorphisms
KW  - Leucemia linfática crónica-Tratamiento
KW  - Chronic lymphocytic leukemia-Treatment
TI  - Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study
DO  - 10.3390/ph18070996
T2  - Pharmaceuticals
VL  - 18
M2  - 996
ER  -